A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma
NCT ID: NCT01248455
Last Updated: 2019-11-19
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
TERMINATED
Clinical Phase
PHASE2
Total Enrollment
9 participants
Study Classification
INTERVENTIONAL
Study Start Date
2010-11-01
Study Completion Date
2015-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Background:
* Recent studies have shown that smoldering multiple myeloma has a high risk of progressing to multiple myeloma, an aggressive type of bone marrow cancer, within 5 years of diagnosis. People with smoldering multiple myeloma have abnormal blood test results that show a high level of monoclonal protein (M-protein) in the blood and of plasma cells in the bone marrow. There are currently no known effective treatments to prevent smoldering multiple myeloma from developing into multiple myeloma, and there are no known tests for determining whether an individual with smoldering multiple myeloma will develop multiple myeloma.
* Certain cells in the immune system, known as natural killer (NK) cells, are active against multiple myeloma. The experimental drug anti-killer cell immunoglobulin-like receptor (anti-KIR) has been shown to help NK cells kill multiple myeloma cells. Researchers are interested in determining whether anti-KIR can be given to individuals with smoldering multiple myeloma to improve their abnormal blood test results.
Objectives:
\- To evaluate the safety and effectiveness of anti-KIR as a treatment for abnormal blood test results related to smoldering multiple myeloma.
Eligibility:
\- Individuals at least 18 years of age who have been diagnosed with smoldering multiple myeloma.
Design:
* Participants will be screened with a physical examination and medical history, and will provide baseline blood, urine, and bone marrow samples before beginning the study drug.
* Participants will receive anti-KIR intravenously for 1 hour, and will be closely monitored for 24 hours after receiving the first dose. If there are no serious side effects, participants will receive five additional anti-KIR doses, one every other month, for a total of six treatment cycles.
* Participants will have monthly visits to provide additional blood and urine samples, and may have additional bone marrow biopsies as directed by the study researchers.
* Participants will have followup visits every 3 to 6 months for up to 5 years after receiving anti-KIR treatment.
* Recent studies have shown that smoldering multiple myeloma has a high risk of progressing to multiple myeloma, an aggressive type of bone marrow cancer, within 5 years of diagnosis. People with smoldering multiple myeloma have abnormal blood test results that show a high level of monoclonal protein (M-protein) in the blood and of plasma cells in the bone marrow. There are currently no known effective treatments to prevent smoldering multiple myeloma from developing into multiple myeloma, and there are no known tests for determining whether an individual with smoldering multiple myeloma will develop multiple myeloma.
* Certain cells in the immune system, known as natural killer (NK) cells, are active against multiple myeloma. The experimental drug anti-killer cell immunoglobulin-like receptor (anti-KIR) has been shown to help NK cells kill multiple myeloma cells. Researchers are interested in determining whether anti-KIR can be given to individuals with smoldering multiple myeloma to improve their abnormal blood test results.
Objectives:
\- To evaluate the safety and effectiveness of anti-KIR as a treatment for abnormal blood test results related to smoldering multiple myeloma.
Eligibility:
\- Individuals at least 18 years of age who have been diagnosed with smoldering multiple myeloma.
Design:
* Participants will be screened with a physical examination and medical history, and will provide baseline blood, urine, and bone marrow samples before beginning the study drug.
* Participants will receive anti-KIR intravenously for 1 hour, and will be closely monitored for 24 hours after receiving the first dose. If there are no serious side effects, participants will receive five additional anti-KIR doses, one every other month, for a total of six treatment cycles.
* Participants will have monthly visits to provide additional blood and urine samples, and may have additional bone marrow biopsies as directed by the study researchers.
* Participants will have followup visits every 3 to 6 months for up to 5 years after receiving anti-KIR treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
NCT01217203
Patients With Multiple Myeloma Experiencing a
First or Second Relapse
COMPLETED
PHASE1
Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma
NCT00999830
Multiple Myeloma
COMPLETED
PHASE2
A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
NCT02903381
Smoldering Multiple Myeloma
COMPLETED
PHASE2
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
NCT01302886
Smoldering Multiple Myeloma
COMPLETED
PHASE2
Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma
NCT03224507
Multiple Myeloma
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background:
* Multiple myeloma (MM) is an incurable plasma cell neoplasm with a median survival of 3-4 years.
* Smoldering multiple myeloma (SMM) is a premalignant plasma cell disorder characterized by monoclonal protein greater than or equal to 3 g/dL or bone marrow plasma cells greater than or equal to 10 percent in the absence of myeloma-related tissue impairment with 51 percent progression to MM at 5 years.
* Current recommendations do not endorse treatment of SMM with chemotherapy.
* Transplanted Natural Killer (NK) Cells have anti-myeloma activity.
* Anti-KIR (IPH2101) is a monoclonal antibody that facilitates NK cell mediated killing of myeloma cells by blocking inhibitory receptors (KIR) on NK cells.
Objectives:
* To assess the response rate of anti-KIR(IPH2101) in patients with SMM
* To evaluate the toxicity of anti-KIR(IPH2101) in patients with SMM
* To evaluate the pharmacokinetic parameters and biological activity of anti-KIR (IPH2101)
Eligibility:
* A confirmed diagnosis of SMM
* Age greater than or equal to 18 years
* Eastern Cooperative Oncology Group (ECOG) performance status in the range of 0-1.
* Without serious co-morbidity that would interfere with receipt of anti-KIR(IPH2101)
Design:
* Single-arm Phase II trial of anti-KIR(IPH2101) for patients with SMM.
* All patients will have initial evaluation and confirmation of diagnosis.
* Patients will receive anti-KIR(IPH2101) (1mg/kg) every other month for 6 cycles.
* Patients will have routine blood work with serum protein electrophoresis (SPEP) and immunofixation monthly.
* Pre- and post-treatment bone marrow biopsies will be obtained for confirmation of diagnosis and correlative studies.
* Patients may donate cellular products or tissues as appropriate for research purposes.
* Optimal two-stage phase II design will be employed, initially enrolling 9 patients. If 3 or more have a positive outcome, then a total of 21 patients will be enrolled in this study.
* Multiple myeloma (MM) is an incurable plasma cell neoplasm with a median survival of 3-4 years.
* Smoldering multiple myeloma (SMM) is a premalignant plasma cell disorder characterized by monoclonal protein greater than or equal to 3 g/dL or bone marrow plasma cells greater than or equal to 10 percent in the absence of myeloma-related tissue impairment with 51 percent progression to MM at 5 years.
* Current recommendations do not endorse treatment of SMM with chemotherapy.
* Transplanted Natural Killer (NK) Cells have anti-myeloma activity.
* Anti-KIR (IPH2101) is a monoclonal antibody that facilitates NK cell mediated killing of myeloma cells by blocking inhibitory receptors (KIR) on NK cells.
Objectives:
* To assess the response rate of anti-KIR(IPH2101) in patients with SMM
* To evaluate the toxicity of anti-KIR(IPH2101) in patients with SMM
* To evaluate the pharmacokinetic parameters and biological activity of anti-KIR (IPH2101)
Eligibility:
* A confirmed diagnosis of SMM
* Age greater than or equal to 18 years
* Eastern Cooperative Oncology Group (ECOG) performance status in the range of 0-1.
* Without serious co-morbidity that would interfere with receipt of anti-KIR(IPH2101)
Design:
* Single-arm Phase II trial of anti-KIR(IPH2101) for patients with SMM.
* All patients will have initial evaluation and confirmation of diagnosis.
* Patients will receive anti-KIR(IPH2101) (1mg/kg) every other month for 6 cycles.
* Patients will have routine blood work with serum protein electrophoresis (SPEP) and immunofixation monthly.
* Pre- and post-treatment bone marrow biopsies will be obtained for confirmation of diagnosis and correlative studies.
* Patients may donate cellular products or tissues as appropriate for research purposes.
* Optimal two-stage phase II design will be employed, initially enrolling 9 patients. If 3 or more have a positive outcome, then a total of 21 patients will be enrolled in this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Multiple Myeloma
Myeloma
Smoldering Multiple Myeloma
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
anti-KIR in Smoldering Multiple Myeloma Patients
Patients will receive anti-KIR(IPH2101) (1mg/kg) every other month for 6 cycles
Group Type
EXPERIMENTAL
(Anti-KIR)
Intervention Type
DRUG
Patients will receive anti-KIR(IPH2101) (1mg/kg) every other month for 6 cycles
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
(Anti-KIR)
Patients will receive anti-KIR(IPH2101) (1mg/kg) every other month for 6 cycles
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of smoldering multiple myeloma (SMM) will be made in accordance with the clinical diagnostic criteria set forth by the International Myeloma Working Group. These criteria include:
* Serum M-protein greater than or equal to 3 g/dl and/or bone marrow plasma cells greater than or equal to 10 percent
* Absence of anemia: Hemoglobin greater than or equal to 10 g/dl
* Absence of renal failure: calculated creatinine clearance (according to modification of diet in renal disease (MDRD)) greater than or equal to 40 ml/min (or alternatively based on standard creatinine level criteria of 2 mg/dl)
* Absence of hypercalcemia: Calcium less than or equal to 10.5 mg/dl
* Absence of lytic bone lesion (skeletal survey)
* The diagnoses will be confirmed by serum/urine protein electrophoresis, immunofixation and light-chain assays; as well as immunohistochemical analyses of the bone marrow biopsy.
* Age greater than or equal to 18 years.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
* Male or female patient who accepts and is able to use recognized effective contraception (oral contraceptives, intrauterine contraceptive device (IUCD), barrier method of contraception in conjunction with spermicidal jelly) through the study and for four months following the final dose of study drug when relevant.
* The patient must be competent to sign an informed consent form.
* Serum M-protein greater than or equal to 3 g/dl and/or bone marrow plasma cells greater than or equal to 10 percent
* Absence of anemia: Hemoglobin greater than or equal to 10 g/dl
* Absence of renal failure: calculated creatinine clearance (according to modification of diet in renal disease (MDRD)) greater than or equal to 40 ml/min (or alternatively based on standard creatinine level criteria of 2 mg/dl)
* Absence of hypercalcemia: Calcium less than or equal to 10.5 mg/dl
* Absence of lytic bone lesion (skeletal survey)
* The diagnoses will be confirmed by serum/urine protein electrophoresis, immunofixation and light-chain assays; as well as immunohistochemical analyses of the bone marrow biopsy.
* Age greater than or equal to 18 years.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
* Male or female patient who accepts and is able to use recognized effective contraception (oral contraceptives, intrauterine contraceptive device (IUCD), barrier method of contraception in conjunction with spermicidal jelly) through the study and for four months following the final dose of study drug when relevant.
* The patient must be competent to sign an informed consent form.
Exclusion Criteria
* Patients with a diagnosis of multiple myeloma (MM) or a clinical suspicion of an ongoing progression into full-blown MM
* Patients without measurable disease defined as serum monoclonal protein (M-protein) less than 1 g/dL.
* Previous treatment having a proven or potential impact on myeloma cell proliferation or survival (including conventional chemotherapies, immunomodulatory drugs (IMiDs), or proteasome inhibitors).
* Use of any investigational agent within the last 3 months.
* Clinical laboratory values at screening:
* Platelet levels less than 75 times 10\^9/L
* Absolute neutrophil count (ANC) levels less than 1 times 10\^9/L
* Bilirubin levels greater than 1.5 upper limit of normal (ULN) ; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 3.0 ULN (grade 1 National Cancer Institute (NCI))
* Primary or associated amyloidosis
* Known abnormal cardiac status with any of the following:
* New York Heart Association (NYHA) stage III or IV congestive heart failure
* Myocardial infarction within the previous 6 months
* Symptomatic and/or treatment-refractory cardiac arrhythmia. Patients with controlled or asymptomatic arrhythmia are not excluded from this study.
* Current active infectious disease or positive serology for:
* Human Immunodeficiency Virus (HIV)
* Hepatitis C Virus (HCV)
* Hepatitis B Surface Antigen
* Severe type of autoimmune disease defined as:
* One which currently requires or previously required long-term systemic immunosuppressive or immunomodulatory therapy (including corticosteroids, administered by systemic route)
* And/or it has a substantial probability to cause an irreversible injury to any tissue (e.g. Hashimoto thyroiditis).
* And/or it is recent or unstable, or has a substantial risk to progress and cause severe complications (e.g. Graves disease)
* Enrollment of other non severe types of auto-immunes disease requiring topical therapy, or non-steroidal inflammatory drugs (NSAIDS) can be considered on a case by case basis by the Principal Investigator.
* History of a lymphoproliferative malignancy.
* History of other malignancy (apart from basal cell carcinoma of the skin or in situ cervical carcinoma) except if the patient has been free of symptoms and without active therapy during at least the previous 5 years.
* Serious concurrent uncontrolled medical disorder.
* History of allograft or solid organ transplantation.
* Any psychological or familial condition potentially interfering with compliance with the study protocol and follow-up schedule.
* Pregnant or lactating women.
* Patients without measurable disease defined as serum monoclonal protein (M-protein) less than 1 g/dL.
* Previous treatment having a proven or potential impact on myeloma cell proliferation or survival (including conventional chemotherapies, immunomodulatory drugs (IMiDs), or proteasome inhibitors).
* Use of any investigational agent within the last 3 months.
* Clinical laboratory values at screening:
* Platelet levels less than 75 times 10\^9/L
* Absolute neutrophil count (ANC) levels less than 1 times 10\^9/L
* Bilirubin levels greater than 1.5 upper limit of normal (ULN) ; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 3.0 ULN (grade 1 National Cancer Institute (NCI))
* Primary or associated amyloidosis
* Known abnormal cardiac status with any of the following:
* New York Heart Association (NYHA) stage III or IV congestive heart failure
* Myocardial infarction within the previous 6 months
* Symptomatic and/or treatment-refractory cardiac arrhythmia. Patients with controlled or asymptomatic arrhythmia are not excluded from this study.
* Current active infectious disease or positive serology for:
* Human Immunodeficiency Virus (HIV)
* Hepatitis C Virus (HCV)
* Hepatitis B Surface Antigen
* Severe type of autoimmune disease defined as:
* One which currently requires or previously required long-term systemic immunosuppressive or immunomodulatory therapy (including corticosteroids, administered by systemic route)
* And/or it has a substantial probability to cause an irreversible injury to any tissue (e.g. Hashimoto thyroiditis).
* And/or it is recent or unstable, or has a substantial risk to progress and cause severe complications (e.g. Graves disease)
* Enrollment of other non severe types of auto-immunes disease requiring topical therapy, or non-steroidal inflammatory drugs (NSAIDS) can be considered on a case by case basis by the Principal Investigator.
* History of a lymphoproliferative malignancy.
* History of other malignancy (apart from basal cell carcinoma of the skin or in situ cervical carcinoma) except if the patient has been free of symptoms and without active therapy during at least the previous 5 years.
* Serious concurrent uncontrolled medical disorder.
* History of allograft or solid organ transplantation.
* Any psychological or familial condition potentially interfering with compliance with the study protocol and follow-up schedule.
* Pregnant or lactating women.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dickran Kazandjian, M.D.
Principal Investigator
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mark J Roschewski, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Cancer Institute (NCI)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P; ASH/FDA Panel on Clinical Endpoints in Multiple Myeloma. Clinically relevant end points and new drug approvals for myeloma. Leukemia. 2008 Feb;22(2):231-9. doi: 10.1038/sj.leu.2405016. Epub 2007 Nov 1.
Reference Type
BACKGROUND
Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bjorkholm M. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol. 2007 May 20;25(15):1993-9. doi: 10.1200/JCO.2006.09.0100. Epub 2007 Apr 9.
Reference Type
BACKGROUND
Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, Dispenzieri A, Kumar S, Clark RJ, Baris D, Hoover R, Rajkumar SV. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009 May 28;113(22):5412-7. doi: 10.1182/blood-2008-12-194241. Epub 2009 Jan 29.
Reference Type
BACKGROUND
Korde N, Carlsten M, Lee MJ, Minter A, Tan E, Kwok M, Manasanch E, Bhutani M, Tageja N, Roschewski M, Zingone A, Costello R, Mulquin M, Zuchlinski D, Maric I, Calvo KR, Braylan R, Tembhare P, Yuan C, Stetler-Stevenson M, Trepel J, Childs R, Landgren O. A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica. 2014 Jun;99(6):e81-3. doi: 10.3324/haematol.2013.103085. Epub 2014 Mar 21. No abstract available.
Reference Type
RESULT
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Informed Consent Form
Document Type: Study Protocol and Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2011-C-0024.html
NIH Clinical Center Detailed Web Page
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11-C-0024
Identifier Type: -
Identifier Source: secondary_id
110024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma
NCT01045460
COMPLETED
PHASE2
Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
NCT02294357
TERMINATED
PHASE2
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
NCT04942067
UNKNOWN
PHASE1/PHASE2
Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy
NCT02020941
TERMINATED
PHASE2
Haploidentical Bone Marrow Stem Cell Transplantation in Patients With Multiple Myeloma
NCT02519114
UNKNOWN
PHASE1/PHASE2
Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant
NCT03015792
TERMINATED
PHASE1
Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma
NCT02415413
ACTIVE_NOT_RECRUITING
PHASE2
Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT
NCT05497102
RECRUITING
PHASE2
Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma
NCT00445068
TERMINATED
PHASE2
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
NCT05561387
RECRUITING
PHASE3
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
NCT01337752
COMPLETED
PHASE2
Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
NCT01572480
COMPLETED
PHASE2
Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)
NCT01109407
TERMINATED
Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation
NCT01058434
COMPLETED
PHASE2
S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
NCT01668719
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
NCT03289299
ACTIVE_NOT_RECRUITING
PHASE2
Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant
NCT00089453
COMPLETED
PHASE1
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
NCT05669989
ACTIVE_NOT_RECRUITING
PHASE2
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma
NCT04370483
ACTIVE_NOT_RECRUITING
EARLY_PHASE1
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
NCT07116616
RECRUITING
PHASE1/PHASE2
Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma
NCT06517017
RECRUITING
PHASE2
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
NCT04579523
NOT_YET_RECRUITING
PHASE1
Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma
NCT06182774
RECRUITING
PHASE3
MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma
NCT01660997
WITHDRAWN
PHASE2
ATRA and Carfilzomib in Plasma Cell Myeloma Patients
NCT06536413
RECRUITING
PHASE1/PHASE2